Biotechnology

PDS Biotechnology

PDS Biotechnology released FY2026 Q1 earnings on May 13 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1324 (forecast USD -0.14)

PDS Biotechnology to Release FY2026 Q1 Earnings on May 13 Pre-Market EST, Forecast EPS USD -0.14

PDS Biotechnology released FY2025 Q4 earnings on March 30 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1465 (forecast USD -0.2)

PDS Biotechnology released FY2025 Annual Earnings on March 30 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7436 (forecast USD -0.8)

PDS Biotechnology to release FY2025 Q4 earnings on March 30, 2026, pre-market EST, forecast EPS USD -0.2

PDS Biotechnology released FY2025 9 Months Earnings on November 13 Pre-Market EST, actual revenue USD 0, actual EPS USD -0.6072

PDS Biotechnology released FY2025 Q3 earnings on November 13 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1922 (forecast USD -0.205)

PDS Biotechnology to release FY2025 Q3 earnings on November 13, Pre-Market EST, with forecasted revenue USD 0 and EPS USD -0.205

PDS Biotechnology Corp Requests Speedier FDA Approval for PDS0101

PDS Biotechnology released FY2025 Q2 earnings on August 13 During-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2055 (forecast USD -0.2333)

PDS Biotechnology released FY2025 Semi-Annual Earnings on August 13 During-Market EST, with actual revenue of USD 0 and EPS of USD -0.4146

PDS Biotechnology to Release FY2025 Q2 Earnings on August 13 During-Market EST, Forecast EPS USD -0.2333

PDS01ADC Expands Phase II Clinical Trial for Metastatic Colorectal Cancer

PDS Biotechnology Annual Shareholders' Meeting Approves Multiple Resolutions

PDS Biotech Hosting Meeting on Versamune® HPV for Head and Neck Cancer Treatment

PDS Biotech Announces Positive Data for Versamune® HPV Therapy

PDS Biotech CEO Participates in Alliance Global Partners Fireside Chat

PDS Biotechnology released FY2025 Q1 earnings on May 14 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2094 (forecast USD -0.2466)

PDS Biotechnology Reports Q1 2025 Net Loss Improvement and Initiation of Clinical Trials

PDS Biotechnology to Release FY2025 Q1 Earnings on May 14, Pre-Market EST, Forecast EPS USD -0.2466

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

ACCS

ACCESS Newswire (AMEX:ACCS) reported Q1 2026 revenues of $5.3 million, a decline from previous quarters. However, customer retention improved to 92%, attributed to enhanced customer experience and new product launches. Operating expenses were reduced, and subscription revenues accounted for 60% of total revenue. The company introduced new products aimed at driving retention and upselling, with a focus on revenue growth through product commercialization and strategic partnerships. Management emphasized the importance of cost discipline while continuing to innovate in the subscription business model.

benzinga_article

ACCESS Newswire

ACCESS Newswire Q1 2026 Earnings Call: Complete Transcript

PDSB

PDS Biotechnology (PDSB) will announce its Q1 earnings on May 13th, before market open. The consensus EPS estimate is -$0.14, reflecting a 33.3% year-over-year increase, with revenue estimated at $0M. In the past three months, there has been one upward revision in EPS estimates and no downward revisions.

PDS Biotechnology Q1 2026 earnings preview

PDS Biotechnology has announced a refinancing of its debt through a $6 million promissory note and a warrant for common shares. The note, carrying 10% interest, is set to close around June 12, 2026, and aims to redeem existing convertible debentures. The company is consolidating its capital-raising activities under a new agreement with Yorkville Securities, while also terminating its previous sales agreement. Analysts rate PDSB stock as a Buy with a $15.00 price target, although concerns about financial performance persist.

Tip Ranks

Nasdaq

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B Riley Financial Pref Share RILYP 6.875 Perp 10/07/24

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

PDS Biotechnology Refinances Debt with New Note, Warrant

PDS Biotechnology has updated its corporate presentation, focusing on the progress of Phase 3 VERSATILE-003, which reports a 39.3-month median overall survival for PDS0101 combinations. The presentation highlights upcoming catalysts, including interim milestones for VERSATILE-003 and data publications for PDS01ADC programs in various cancers, expected in 2026-2027. The Phase 3 trial is FDA-aligned on the PFS interim endpoint, with 252 participants involved. The updated presentation was filed on April 24, 2026.

TradingView

PDS Biotechnology updates corporate presentation highlighting Phase 3 VERSATILE-003, 39.3m mOS and upcoming catalysts

WYHG

PDS Biotechnology pre-market up 7.53%; Wing Yip Food China pre-market down 4.41%; Freecast pre-market up 63.10%; iTonic pre-market up 40.99%; MaxLinear pre-market up 37.49%

Price Alert

Wing Yip Food China

Pre-market hot trades in US stocks: PDS Biotechnology up 7.53% in pre-market; Wing Yip Food China down 4.41% in pre-market

ORBS

Eightco pre-market up 9.68%; PDS Biotechnology pre-market down 9.38%; Psyence Biomedical pre-market up 94.38%; YXT.COM pre-market up 63.76%; Able View Global pre-market up 46.55%

Eightco

Pre-market hot trades in US stocks: Eightco up 9.68% in pre-market; PDS Biotechnology down 9.38% in pre-market

PDS Biotechnology Corporation (PDSB) reported positive interim Phase 2 results for its immunocytokine PDS01ADC in metastatic colorectal cancer (mCRC). Key findings from a nine-patient cohort included a 77.8% objective response rate at six months and an 85% two-year survival rate. The therapy combines PDS01ADC with floxuridine, delivered via an FDA-approved hepatic artery infusion pump. Following the announcement, PDSB's stock rose 28.30% to $1.36, and further increased to $1.41 in overnight trading.

nasdaq

PDS Biotech Reports Strong Interim Data With PDS01ADC In Colorectal Cancer, Stock Up

PDS Biotechnology(PDSB.US)